Use of anti-nerve growth factors monoclonal antibodies as a treatment for osteoarthritis in dogs

Abstract

Canine osteoarthritis (OA) is a degenerative disease causing chronic pain, loss of joint function and impaired mobility. It is estimated that OA affects approximately 20% of dogs ≥1 year old and 90% of dogs >5 years old [1]. Osteoarthritis is also a major issue worldwide for veterinarians, owners and breeders. Today, there is no efficient treatment able to treat the primary cause(s) of osteoarthritis and curing the clinical signs of pain. The objective of accessible therapies is to alleviate joint pain, retard the progression of the disease and improve motility, and the final goal is to enhance the global quality of life.